glp 1 drugs and mental health An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive disorders GLP-1 Medications and Mental Health:

Hissa, M

6.9.2 MicroRNAs Previous studies have indicated that certain miRNAs, such as let-7a, miR-221/miR-222, and miR-92b, are involved in follicular development and follicular atresia

The investigators are assessing a three-point major adverse cardiovascular event endpoint (myocardial infarction, stroke, and cardiovascular death), over an estimated maximum of 54months (NCT04255433, estimated study completion in October 2024)

Many of the neuroprotective, neurodegenerative, psychiatric, and addiction-related applications discussed remain investigational, and no GLP-1 receptor agonist is currently approved by regulatory authorities for the treatment or prevention of Alzheimers disease, Parkinsons disease, depression, substance use disorders, or other neurological indications unless specifically stated otherwise

The fix is simple

Business Insider